In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”.
A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
hepatocellular carcinoma, lenvatinib, propensity score (PS) matching (PSM), sorafenib, progression-free survival
Citation
Kuo Y-H, Lu S-N, Chen Y-Y, Kee K-M, Yen Y-H, Hung C-H, Hu T-H, Chen C-H and Wang J-H (2021) Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front. Oncol. 11:823960. doi: 10.3389/fonc.2021.823960
Received
28 November 2021
Accepted
01 December 2021
Published
14 December 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2021
Updates
Copyright
© 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing-Houng Wang, jinghoung2001@yahoo.com.tw
This article was submitted to Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.